SCHEMBL2218147

SCHEMBL2218147

COc1ccc(C(=O)c2cnc(Cl)cc2Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.62
RAB9A P51151 3/20 0.62
KMT2A Q03164 3/20 0.57
HTT P42858 4/20 0.54
NPSR1 Q6W5P4 4/20 0.54
MAPK1 P28482 4/20 0.54
GAA P10253 2/20 0.54
HPGD P15428 3/20 0.53
NPC1 O15118 2/20 0.51
POLB P06746 1/20 0.50
ALDH1A1 P00352 5/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
RXFP1 Q9HBX9 2/20 0.48
LMNA P02545 3/20 0.47
ALOX15 P16050 1/20 0.47
RAF1 P04049 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9989146 0.83 MAPT (0.51) MAPTRAB9AKMT2AHTTNPSR1
SCHEMBL2214438 0.80 KCNQ3 (0.48) RAB9ANPC1RXFP1VNN1
SCHEMBL9726804 0.80 MAPT (0.82) MAPTRAB9AKMT2AHTTNPSR1
SCHEMBL15067437 0.78 RXFP1 (0.65) MAPTRAB9AKMT2AHTTNPSR1
SCHEMBL4743098 0.77 MAPT (1.00) MAPTRAB9AKMT2AHTTNPSR1
SCHEMBL28662886 0.77 NNMT (0.42) MAPTKMT2AHTTHPGDCYP1A2
SCHEMBL2211416 0.77 CYP11B1 (0.44) MAPTKMT2AMAPK1MEN1VNN1
SCHEMBL20892510 0.76 HPGD (0.60) MAPTRAB9AKMT2ANPSR1MAPK1
SCHEMBL3468717 0.75 MAPT (0.73) MAPTRAB9AKMT2AHTTNPSR1
SCHEMBL30823770 0.75 MAPT (0.73) MAPTRAB9AKMT2AHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709046-B1 P38 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-07-27 EP disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed
EP-1709046-A1 P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-11 EP disclosed
WO-2005073232-A1 P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161673-A1 P38 kinase inhibitors MAPK1, MAPK7, MAP3K1 MAPT 1468/4885RAB9A 2179/4885KMT2A 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.